Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Meningococcal Vaccination

On October 29, 2014, the Food and Drug Administration (FDA) licensed the first serogroup B meningococcal vaccine (Trumenba®). FDA approved this vaccine for use in people 10 through 25 years old as a 3-dose series. On January 23, 2015, FDA licensed a second serogroup B meningococcal vaccine (Bexsero®). FDA approved this vaccine for use in people 10 through 25 years old as a 2-dose series. Clinicians can use serogroup B meningococcal vaccines for people 10 through 25 years old consistent with the labeled indication.

Vaccines are now available that help protect against all three serogroups (B, C, and Y) of meningococcal disease that are commonly seen in the United States:

  • Meningococcal conjugate vaccine (Menactra®, Menveo® and MenHibrix®)
  • Meningococcal polysaccharide vaccine (Menomune®)
  • Serogroup B meningococcal vaccine (Bexsero® and Trumenba®)

For more information on meningococcal vaccines and who should receive them, visit the Meningococcal Vaccine site or Recommendations of the Advisory Committee on Immunization Practices.

What You Need to Know about Meningococcal Vaccines

Meningococcal Vaccine Resources for Health Care Professionals

Vaccination Coverage

Top of Page

Related Pages

  • Have You Heard About How To Prevent Meningococcal Disease?
    View this video on CDC-TV or on YouTube
Top